Abstract:Rationale: SUMOylation regulates a plethora of biological processes, and its inhibitors are currently under investigation in clinical trials as anticancer agents. Thus, identifying new targets with site-specific SUMOylation and defining their biological functions will not only provide new mechanistic insights into the SUMOylation signaling but also open an avenue for developing new strategy for cancer therapy. MORC family CW-type zinc finger 2 (MORC2) is a newly identified chromatin-remodeling enzyme with an emerging role in the DNA damage response (DDR), but its regulatory mechanism remains enigmatic. Methods: In vivo and in vitro SUMOylation assays were used to determine the SUMOylation levels of MORC2. Overexpression and knockdown of SUMO-associated enzymes were used to detect their effects on MORC2 SUMOylation. The effect of dynamic MORC2 SUMOylation on the sensitivity of breast cancer cells to chemotherapeutic drugs was examined through in vitro and in vivo functional assays. Immunoprecipitation, GST pull-down, MNase, and chromatin segregation assays were used to explore the underlying mechanisms. Results: Here, we report that MORC2 is modified by small ubiquitin-like modifier 1 (SUMO1) and SUMO2/3 at lysine 767 (K767) in a SUMO-interacting motif dependent manner. MORC2 SUMOylation is induced by SUMO E3 ligase tripartite motif containing 28 (TRIM28) and reversed by deSUMOylase sentrin-specific protease 1 (SENP1). Intriguingly, SUMOylation of MORC2 is decreased at the early stage of DNA damage induced by chemotherapeutic drugs that attenuate the interaction of MORC2 with TRIM28. MORC2 deSUMOylation induces transient chromatin relaxation to enable efficient DNA repair. At the relatively late stage of DNA damage, MORC2 SUMOylation is restored, and SUMOylated MORC2 interacts with protein kinase CSK21 (casein kinase II subunit alpha), which in turn phosphorylates DNA-PKcs (DNA-dependent protein kinase catalytic subunit), thus promoting DNA repair. Notably, expression of a SUMOylation-deficient mutant MORC2 or administration of SUMO inhibitor enhances the sensitivity of breast cancer cells to DNA-damaging chemotherapeutic drugs. Conclusions: Collectively, these findings uncover a novel regulatory mechanism of MORC2 by SUMOylation and reveal the intricate dynamics of MORC2 SUMOylation important for proper DDR. We also propose a promising strategy to sensitize MORC2-driven breast tumors to chemotherapeutic drugs by inhibition of the SUMO pathway.

Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer

Dimerization of MORC2 Through Its C-terminal Coiled-Coil Domain Enhances Chromatin Dynamics and Promotes DNA Repair

USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells

MORC2 phosphorylation fine tunes its DNA compaction activity

USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response

MORC2 Regulates DNA Damage Response Through a PARP1-dependent Pathway.

MORC2 Signaling Integrates Phosphorylation-Dependent, ATPase-coupled Chromatin Remodeling During the DNA Damage Response.

Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer

Chromatin remodeling protein MORC2 promotes a breast cancer stem-like phenotype by regulating ALDH1A3 expression

NMR metabolomic profiling reveals new roles of SUMOylation in DNA damage response

SUMOylation Stabilizes Hssb1 and Enhances the Recruitment of NBS1 to DNA Damage Sites

SUMOylation Inhibits FOXM1 Activity and Delays Mitotic Transition

Stabilization of MORC2 by Estrogen and Antiestrogens Through GPER1-PRKACA-CMA Pathway Contributes to Estrogen-Induced Proliferation and Endocrine Resistance of Breast Cancer Cells

Repression of the SUMO-conjugating enzyme UBC9 is associated with lowered double minutes and reduced tumor progression

Destabilization of microrchidia family CW‐type zinc finger 2 via the cyclin‐dependent kinase 1‐chaperone‐mediated autophagy pathway promotes mitotic arrest and enhances cancer cellular sensitivity to microtubule‐targeting agents

Sumoylation As an Emerging Target in Therapeutics Against Cancer

Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer

Novel Insights into the Role of Chromatin Remodeler MORC2 in Cancer

SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer.

Sumoylation as an Emerging Target in Therapeutics against Cancer.

O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progression